<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316589</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-011</org_study_id>
    <nct_id>NCT00316589</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients</brief_title>
  <official_title>A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts &gt;200 - 750/µl.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gather information on the safety and immunogenicity of an
      investigational smallpox vaccine in HIV infected populations. Subjects will receive two
      vaccinations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Related Grade &gt;=3 Adverse Events</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Incidence of any Grade 3 or higher adverse drug reaction (missing, unknown, not evaluable, possibly, probably, or definitely related) to the study vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Local Adverse Events</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Incidence and intensity of solicited local AEs (pain, erythema, swelling). Percentages based on subjects with at least one completed diary card.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited General Adverse Events</measure>
    <time_frame>within 8 days after any vaccination</time_frame>
    <description>Incidence of solicited general AEs (increased body temperature, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Adverse Events: Incidence</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Incidence of any unsolicited adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Adverse Events: Intensity</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Occurrence of unsolicited adverse events by Intensity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Adverse Events: Relationship to Vaccination</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Occurrence of unsolicited adverse events by relationship to study vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ T-cell Counts</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Median CD4+ T-cell counts over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8+ T-cell Counts</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Median CD8+ T-cell counts over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Load</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Viral load (HIV-1 RNA levels) over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT Seroconversion Rate</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRNT GMT</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA Seroconversion Rate</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA GMT</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT IFN-γ: Response Rate</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Response rate based on number of subjects with response in an interferon gamma (IFN-γ) ELISPOT assay. Response is defined as the appearance of a signal in subjects that had no signal at Baseline or a relative increase by a factor of ≥1.7 compared to Baseline in subjects that had a signal at Baseline. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISPOT IFN-γ: SFU</measure>
    <time_frame>within 32 weeks</time_frame>
    <description>Median number of interferon gamma (IFN-γ) secreting peripheral blood mononuclear cells (PBMC) in response to stimulation with MVA-BN detected by ELISPOT assay.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">581</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control group with and without a history of previous smallpox vaccination IMVAMUNE (MVA-BN)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected, vaccinia-naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects without a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-infected, vaccinia-experienced</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE (MVA-BN)</intervention_name>
    <description>2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous</description>
    <arm_group_label>HIV-infected, vaccinia-experienced</arm_group_label>
    <arm_group_label>HIV-infected, vaccinia-naive</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
    <other_name>IMVANEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Genders eligible for Study: Both

          -  Age: between 18 and 55 years

          -  Healthy volunteers are accepted

        Inclusion Criteria:

          -  Subjects tested positive for HIV-1 infection (HIV-infected subjects).

          -  Subjects that are tested negative for HIV (Healthy subjects).

          -  Either on stable antiretroviral therapy or not on antiretroviral therapy.

          -  CD4 cells &gt; = 200 - 750/µl.

          -  Subjects must be in good general health except for HIV infection.

          -  Women must not be pregnant and use an acceptable method of contraception.

        Exclusion Criteria:

          -  Impairment of immunologic function (other than HIV infection).

          -  History of coronary heart disease, myocardial infarction, angina, congestive heart
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood
             pressure.

          -  Uncontrolled serious infection.

          -  History of or active autoimmune disease.

          -  History or clinical manifestation of clinically significant and severe hematological,
             renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal
             disorders.

          -  History of an immediate family member (father, mother, brother, or sister) who has had
             onset of ischemic heart disease before the age of 50 years.

          -  High risk of developing a myocardial infarction or coronary death.

          -  History of intravenous drug abuse (within the last 12 months).

          -  Known allergy to egg or aminoglycoside (gentamicin).

          -  History of anaphylaxis or severe allergic reaction.

          -  Subjects undergoing treatment for tuberculosis infection or disease.

          -  Chronic administration of systemic immuno-suppressants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edgar Turner Overton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Vaccine Research Clinic; University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health for Life Clinic, PLLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSI Clinical Trials, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AltaMed Health Services</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center, East Bay AIDS Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultive Medicine</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northpoint Medical, PA</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Kinder Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases of NW Florida</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta ID Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northstar Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine; Division of Infectious Disease</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-2859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa, Division of Infectious Diseases</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemechek Health Renewal</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University, Center for Vaccine Dev.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immuniodeficiency Clinic, ECMC</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtity of Rochester School of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research Services</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown Medical School</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Carolina</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University, AIDS Clinical Trials Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicholaos C. Bellos, MD PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley AIDS Council</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diversified Medical Practices</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research P.R., Inc.</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternal Infant Studies Center (CEMI)</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, Wagner E, von Krempelhuber A, Virgin G, Meyer TP, Müller J, Bädeker N, Grünert R, Young P, Rösch S, Maclennan J, Arndtz-Wiedemann N, Chaplin P. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum Infect Dis. 2015 May 5;2(2):ofv040. doi: 10.1093/ofid/ofv040. eCollection 2015 Apr. Erratum in: Open Forum Infect Dis. 2016 Jan;3(1):ofv183.</citation>
    <PMID>26380340</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 19, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2006</study_first_posted>
  <results_first_submitted>December 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2019</results_first_posted>
  <last_update_submitted>December 7, 2018</last_update_submitted>
  <last_update_submitted_qc>December 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>treatment experienced</keyword>
  <keyword>treatment vaccinia naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy naïve</title>
          <description>Healthy, smallpox vaccine-naïve subjects</description>
        </group>
        <group group_id="P2">
          <title>HIV naïve</title>
          <description>HIV-infected, smallpox vaccine-naïve subjects</description>
        </group>
        <group group_id="P3">
          <title>Healthy Experienced</title>
          <description>Healthy, smallpox vaccine-experienced subjects</description>
        </group>
        <group group_id="P4">
          <title>HIV Experienced</title>
          <description>HIV-infected, smallpox vaccine-experienced subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="352"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="328"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject unwilling/unable to comply</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy naïve</title>
          <description>Healthy, smallpox vaccine-naïve subjects</description>
        </group>
        <group group_id="B2">
          <title>HIV naïve</title>
          <description>HIV-infected, smallpox vaccine-naïve subjects</description>
        </group>
        <group group_id="B3">
          <title>Healthy Experienced</title>
          <description>Healthy, smallpox vaccine-experienced subjects</description>
        </group>
        <group group_id="B4">
          <title>HIV Experienced</title>
          <description>HIV-infected, smallpox vaccine-experienced subjects</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="351"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="131"/>
            <count group_id="B5" value="579"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="7.14"/>
                    <measurement group_id="B2" value="36.8" spread="7.98"/>
                    <measurement group_id="B3" value="45.6" spread="8.88"/>
                    <measurement group_id="B4" value="44.6" spread="5.13"/>
                    <measurement group_id="B5" value="37.5" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="110"/>
                    <measurement group_id="B5" value="440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="324"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="124"/>
                    <measurement group_id="B5" value="545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events</title>
        <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE)</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE)</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE with intensity &gt;= Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE assessed as related to vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related Grade &gt;=3 Adverse Events</title>
        <description>Incidence of any Grade 3 or higher adverse drug reaction (missing, unknown, not evaluable, possibly, probably, or definitely related) to the study vaccine</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Related Grade &gt;=3 Adverse Events</title>
          <description>Incidence of any Grade 3 or higher adverse drug reaction (missing, unknown, not evaluable, possibly, probably, or definitely related) to the study vaccine</description>
          <population>Full Analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited Local Adverse Events</title>
        <description>Incidence and intensity of solicited local AEs (pain, erythema, swelling). Percentages based on subjects with at least one completed diary card.</description>
        <time_frame>within 8 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Local Adverse Events</title>
          <description>Incidence and intensity of solicited local AEs (pain, erythema, swelling). Percentages based on subjects with at least one completed diary card.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="246"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited General Adverse Events</title>
        <description>Incidence of solicited general AEs (increased body temperature, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.</description>
        <time_frame>within 8 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited General Adverse Events</title>
          <description>Incidence of solicited general AEs (increased body temperature, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship to vaccination. Percentages based on subjects with at least one completed diary card.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased body temperature: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased body temperature: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased body temperature: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Grade &gt;=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unsolicited Adverse Events: Incidence</title>
        <description>Incidence of any unsolicited adverse events</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Unsolicited Adverse Events: Incidence</title>
          <description>Incidence of any unsolicited adverse events</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unsolicited Adverse Events: Intensity</title>
        <description>Occurrence of unsolicited adverse events by Intensity</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Unsolicited Adverse Events: Intensity</title>
          <description>Occurrence of unsolicited adverse events by Intensity</description>
          <population>Full Analysis Set</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="590"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="410"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unsolicited Adverse Events: Relationship to Vaccination</title>
        <description>Occurrence of unsolicited adverse events by relationship to study vaccine</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Unsolicited Adverse Events: Relationship to Vaccination</title>
          <description>Occurrence of unsolicited adverse events by relationship to study vaccine</description>
          <population>Full Analysis Set</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="351"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unrelated/None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlikely</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="590"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ T-cell Counts</title>
        <description>Median CD4+ T-cell counts over time</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Full Analysis Set (HIV infected subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell Counts</title>
          <description>Median CD4+ T-cell counts over time</description>
          <population>Full Analysis Set (HIV infected subjects)</population>
          <units>CD4 count (cells/µL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445.0" lower_limit="156" upper_limit="1108"/>
                    <measurement group_id="O2" value="456.0" lower_limit="186" upper_limit="922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="434.5" lower_limit="147" upper_limit="2029"/>
                    <measurement group_id="O2" value="455.0" lower_limit="136" upper_limit="1107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438.5" lower_limit="125" upper_limit="1045"/>
                    <measurement group_id="O2" value="447.0" lower_limit="213" upper_limit="1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.5" lower_limit="138" upper_limit="1056"/>
                    <measurement group_id="O2" value="435.0" lower_limit="273" upper_limit="762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD8+ T-cell Counts</title>
        <description>Median CD8+ T-cell counts over time</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Full Analysis Set (HIV infected subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>CD8+ T-cell Counts</title>
          <description>Median CD8+ T-cell counts over time</description>
          <population>Full Analysis Set (HIV infected subjects)</population>
          <units>CD8 count (cells/µL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="771.0" lower_limit="62" upper_limit="3210"/>
                    <measurement group_id="O2" value="877.5" lower_limit="188" upper_limit="1914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779.0" lower_limit="208" upper_limit="3449"/>
                    <measurement group_id="O2" value="848.0" lower_limit="219" upper_limit="2066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="749.0" lower_limit="177" upper_limit="3238"/>
                    <measurement group_id="O2" value="798.5" lower_limit="229" upper_limit="2319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="834.0" lower_limit="196" upper_limit="2457"/>
                    <measurement group_id="O2" value="729.0" lower_limit="245" upper_limit="1870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Load</title>
        <description>Viral load (HIV-1 RNA levels) over time</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Full Analysis Set (HIV infected subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load</title>
          <description>Viral load (HIV-1 RNA levels) over time</description>
          <population>Full Analysis Set (HIV infected subjects)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt;400</title>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>400 - &lt;1000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1000 - &lt;10000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=10000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt;400</title>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>400 - &lt;1000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1000 - &lt;10000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=10000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt;400</title>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>400 - &lt;1000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1000 - &lt;10000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=10000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt;400</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>400 - &lt;1000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1000 - &lt;10000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=10000</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRNT Seroconversion Rate</title>
        <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT Seroconversion Rate</title>
          <description>Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (6) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="1.1" upper_limit="14.6"/>
                    <measurement group_id="O2" value="14.5" lower_limit="10.3" upper_limit="19.6"/>
                    <measurement group_id="O3" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O4" value="45.1" lower_limit="34.6" upper_limit="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="8.7" upper_limit="29.9"/>
                    <measurement group_id="O2" value="21.6" lower_limit="16.6" upper_limit="27.3"/>
                    <measurement group_id="O3" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O4" value="62.6" lower_limit="51.9" upper_limit="72.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="66.1" upper_limit="88.6"/>
                    <measurement group_id="O2" value="58.1" lower_limit="51.6" upper_limit="64.4"/>
                    <measurement group_id="O3" value="80.0" lower_limit="28.4" upper_limit="99.5"/>
                    <measurement group_id="O4" value="76.9" lower_limit="66.9" upper_limit="85.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" lower_limit="66.1" upper_limit="88.6"/>
                    <measurement group_id="O2" value="52.7" lower_limit="46.2" upper_limit="59.1"/>
                    <measurement group_id="O3" value="80.0" lower_limit="28.4" upper_limit="99.5"/>
                    <measurement group_id="O4" value="78.0" lower_limit="68.1" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                    <measurement group_id="O2" value="12.5" lower_limit="5.2" upper_limit="24.1"/>
                    <measurement group_id="O3" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O4" value="64.7" lower_limit="38.3" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PRNT GMT</title>
        <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>PRNT GMT</title>
          <description>Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.0" upper_limit="1.8"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.6" upper_limit="2.4"/>
                    <measurement group_id="O3" value="12.0" lower_limit="0.7" upper_limit="205.6"/>
                    <measurement group_id="O4" value="5.5" lower_limit="3.6" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.1" upper_limit="2.4"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.2" upper_limit="3.7"/>
                    <measurement group_id="O3" value="108.9" lower_limit="2.9" upper_limit="4150.0"/>
                    <measurement group_id="O4" value="20.5" lower_limit="12.6" upper_limit="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.3" upper_limit="3.3"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.8" upper_limit="4.9"/>
                    <measurement group_id="O3" value="100.2" lower_limit="2.7" upper_limit="3721.7"/>
                    <measurement group_id="O4" value="42.3" lower_limit="26.9" upper_limit="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="12.3" upper_limit="35.3"/>
                    <measurement group_id="O2" value="13.0" lower_limit="9.6" upper_limit="17.5"/>
                    <measurement group_id="O3" value="354.5" lower_limit="66.2" upper_limit="1899.2"/>
                    <measurement group_id="O4" value="88.9" lower_limit="59.2" upper_limit="133.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="9.2" upper_limit="24.0"/>
                    <measurement group_id="O2" value="9.7" lower_limit="7.2" upper_limit="12.9"/>
                    <measurement group_id="O3" value="171.2" lower_limit="62.2" upper_limit="470.9"/>
                    <measurement group_id="O4" value="76.1" lower_limit="52.0" upper_limit="111.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.2" upper_limit="6.3"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.0" upper_limit="5.6"/>
                    <measurement group_id="O3" value="58.0" lower_limit="11.1" upper_limit="303.2"/>
                    <measurement group_id="O4" value="53.1" lower_limit="27.2" upper_limit="103.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA Seroconversion Rate</title>
        <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Per-protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA Seroconversion Rate</title>
          <description>Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Per-protocol set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" lower_limit="14.1" upper_limit="37.8"/>
                    <measurement group_id="O2" value="29.5" lower_limit="23.8" upper_limit="35.7"/>
                    <measurement group_id="O3" value="80.0" lower_limit="28.4" upper_limit="99.5"/>
                    <measurement group_id="O4" value="58.2" lower_limit="47.4" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7" lower_limit="68.1" upper_limit="90.0"/>
                    <measurement group_id="O2" value="69.3" lower_limit="63.1" upper_limit="75.1"/>
                    <measurement group_id="O3" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="79.1" lower_limit="69.3" upper_limit="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="90.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="97.1" lower_limit="94.1" upper_limit="98.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="94.5" lower_limit="87.6" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" lower_limit="87.9" upper_limit="99.6"/>
                    <measurement group_id="O2" value="92.1" lower_limit="88.0" upper_limit="95.2"/>
                    <measurement group_id="O3" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="90.1" lower_limit="82.1" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7" lower_limit="47.2" upper_limit="82.7"/>
                    <measurement group_id="O2" value="46.4" lower_limit="33.0" upper_limit="60.3"/>
                    <measurement group_id="O3" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O4" value="76.5" lower_limit="50.1" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA GMT</title>
        <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Per-protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMT</title>
          <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
          <population>Per-protocol Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.2" upper_limit="3.0"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.5" upper_limit="6.0"/>
                    <measurement group_id="O3" value="37.1" lower_limit="2.6" upper_limit="529.8"/>
                    <measurement group_id="O4" value="33.3" lower_limit="21.5" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.1" upper_limit="6.5"/>
                    <measurement group_id="O2" value="9.4" lower_limit="6.9" upper_limit="12.8"/>
                    <measurement group_id="O3" value="260.6" lower_limit="36.6" upper_limit="1858.0"/>
                    <measurement group_id="O4" value="89.9" lower_limit="56.0" upper_limit="144.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" lower_limit="34.9" upper_limit="90.5"/>
                    <measurement group_id="O2" value="46.6" lower_limit="35.7" upper_limit="60.9"/>
                    <measurement group_id="O3" value="461.1" lower_limit="63.8" upper_limit="3332.9"/>
                    <measurement group_id="O4" value="220.1" lower_limit="154.5" upper_limit="313.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="526.2" lower_limit="400.2" upper_limit="691.8"/>
                    <measurement group_id="O2" value="299.8" lower_limit="253.4" upper_limit="354.7"/>
                    <measurement group_id="O3" value="612.9" lower_limit="107.6" upper_limit="3490.5"/>
                    <measurement group_id="O4" value="588.4" lower_limit="463.6" upper_limit="746.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312.9" lower_limit="235.5" upper_limit="415.8"/>
                    <measurement group_id="O2" value="175.5" lower_limit="143.6" upper_limit="214.6"/>
                    <measurement group_id="O3" value="403.4" lower_limit="77.0" upper_limit="2112.0"/>
                    <measurement group_id="O4" value="453.1" lower_limit="370.7" upper_limit="553.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" lower_limit="14.7" upper_limit="70.1"/>
                    <measurement group_id="O2" value="24.3" lower_limit="12.7" upper_limit="46.5"/>
                    <measurement group_id="O3" value="89.5" lower_limit="3.6" upper_limit="2230.7"/>
                    <measurement group_id="O4" value="203.9" lower_limit="152.7" upper_limit="272.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT IFN-γ: Response Rate</title>
        <description>Response rate based on number of subjects with response in an interferon gamma (IFN-γ) ELISPOT assay. Response is defined as the appearance of a signal in subjects that had no signal at Baseline or a relative increase by a factor of ≥1.7 compared to Baseline in subjects that had a signal at Baseline. Percentages based on number of subjects with data available.</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Elispot Analysis Set (subset of the Per-protocol Set with ELISPOT data available)</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT IFN-γ: Response Rate</title>
          <description>Response rate based on number of subjects with response in an interferon gamma (IFN-γ) ELISPOT assay. Response is defined as the appearance of a signal in subjects that had no signal at Baseline or a relative increase by a factor of ≥1.7 compared to Baseline in subjects that had a signal at Baseline. Percentages based on number of subjects with data available.</description>
          <population>Elispot Analysis Set (subset of the Per-protocol Set with ELISPOT data available)</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="19.7" upper_limit="61.5"/>
                    <measurement group_id="O2" value="28.6" lower_limit="14.6" upper_limit="46.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O4" value="26.5" lower_limit="16.5" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="19.7" upper_limit="61.5"/>
                    <measurement group_id="O2" value="20.0" lower_limit="8.4" upper_limit="36.9"/>
                    <measurement group_id="O3" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O4" value="29.4" lower_limit="19.0" upper_limit="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" lower_limit="26.8" upper_limit="69.4"/>
                    <measurement group_id="O2" value="40.0" lower_limit="23.9" upper_limit="57.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O4" value="29.4" lower_limit="19.0" upper_limit="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                    <measurement group_id="O2" value="25.7" lower_limit="12.5" upper_limit="43.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O4" value="29.4" lower_limit="19.0" upper_limit="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="29.8" upper_limit="74.3"/>
                    <measurement group_id="O2" value="36.8" lower_limit="16.3" upper_limit="61.6"/>
                    <measurement group_id="O3" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O4" value="23.1" lower_limit="5.0" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISPOT IFN-γ: SFU</title>
        <description>Median number of interferon gamma (IFN-γ) secreting peripheral blood mononuclear cells (PBMC) in response to stimulation with MVA-BN detected by ELISPOT assay.</description>
        <time_frame>within 32 weeks</time_frame>
        <population>Elispot Analysis Set (subset of the Per-protocol Set with ELISPOT data available)</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy naïve</title>
            <description>Healthy, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O2">
            <title>HIV naïve</title>
            <description>HIV-infected, smallpox vaccine-naïve subjects</description>
          </group>
          <group group_id="O3">
            <title>Healthy Experienced</title>
            <description>Healthy, smallpox vaccine-experienced subjects</description>
          </group>
          <group group_id="O4">
            <title>HIV Experienced</title>
            <description>HIV-infected, smallpox vaccine-experienced subjects</description>
          </group>
        </group_list>
        <measure>
          <title>ELISPOT IFN-γ: SFU</title>
          <description>Median number of interferon gamma (IFN-γ) secreting peripheral blood mononuclear cells (PBMC) in response to stimulation with MVA-BN detected by ELISPOT assay.</description>
          <population>Elispot Analysis Set (subset of the Per-protocol Set with ELISPOT data available)</population>
          <units>Spot Forming Units / 10^6 PBMC</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="230"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="239"/>
                    <measurement group_id="O3" value="155.0" lower_limit="88" upper_limit="542"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="0" upper_limit="497"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="806"/>
                    <measurement group_id="O3" value="71.0" lower_limit="0" upper_limit="322"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="0" upper_limit="501"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="371"/>
                    <measurement group_id="O3" value="569.0" lower_limit="100" upper_limit="1143"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="0" upper_limit="754"/>
                    <measurement group_id="O2" value="72.0" lower_limit="0" upper_limit="822"/>
                    <measurement group_id="O3" value="54.0" lower_limit="0" upper_limit="751"/>
                    <measurement group_id="O4" value="57.5" lower_limit="0" upper_limit="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="599"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="505"/>
                    <measurement group_id="O3" value="71.0" lower_limit="0" upper_limit="96"/>
                    <measurement group_id="O4" value="53.0" lower_limit="0" upper_limit="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="0" upper_limit="942"/>
                    <measurement group_id="O2" value="73.0" lower_limit="0" upper_limit="370"/>
                    <measurement group_id="O3" value="596.0" lower_limit="454" upper_limit="738"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Healthy naïve</title>
          <description>Healthy, smallpox vaccine-naïve subjects</description>
        </group>
        <group group_id="E2">
          <title>HIV naïve</title>
          <description>HIV-infected, smallpox vaccine-naïve subjects</description>
        </group>
        <group group_id="E3">
          <title>Healthy Experienced</title>
          <description>Healthy, smallpox vaccine-experienced subjects</description>
        </group>
        <group group_id="E4">
          <title>HIV Experienced</title>
          <description>HIV-infected, smallpox vaccine-experienced subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Anticonvulsant toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Injection site pruritis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Lead, Clinical Operations</name_or_title>
      <organization>Bavarian Nordic A/S</organization>
      <phone>+45 3326 ext 8383</phone>
      <email>info@bavarian-nordic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

